Toll-like receptors (TLRs) and myeloid differentiation primary response protein 88 (MYD88) gene polymorphisms may be involved in the pathogenesis of Hodgkin's lymphoma (HL) through altered immunoregulatory and inflammatory responses. A candidate-gene association study was conducted to investigate the association between TLR9 À1237T4C, TLR9 2848A4G, MYD88 À938C4A and MYD88 1944C4G gene polymorphisms and the risk for HL. The impact of haplotypes was also examined. The study showed that carriership for À1237C and 2848A was associated with an increased risk for HL (odds ratio (OR)¼2.53 (1.36-4.71) and OR¼6.20 (1.3-28.8)). The MYD88 polymorphisms produced nonsignificant results. The estimated frequencies of the TLR9/1237C-2848A and MYD88/938C-1944G haplotypes were also significantly different between HL and controls (Po0.01). In addition, a significant difference between HL and controls was observed for the TLR9/1237C-TLR9/ 2848A-MYD88/938C-MYD88/1944C haplotypes (Po0.01). In conclusion, our study showed that TLR polymorphisms, and TLR9 and MYD88 haplotypes are related to the development of HL.
INTRODUCTION
Hodgkin's lymphoma (HL) is an uncommon neoplasm with an ageadjusted incidence of 2.5-3.1 per 10E5 in the Western world. 1, 2 Involved lymph nodes show an inflammatory cellular background and rare Reed Sternberg (RS) cells, which are the malignant cells of HL. The pathogenesis of HL remains unclear. A transcription factor that has been implicated in the pathogenesis of HL is nuclear factorkB (NF-kB), a pleiotropic mediator of inflammation. Strong constitutive NF-kB activity is a common feature of HL cell lines 3 and is required for the proliferation and survival of RS cells. 3 However, the cause of NF-kB triggering is still elusive, but there is evidence that it may be linked to the Epstein Bar Virus (EBV), a herpes virus that has been associated with HL. [4] [5] [6] [7] [8] [9] In addition, one of the EBV proteins, the Latent Membrane Protein 1 (LMP1), activates NF-kB, stimulates cell proliferation and prevents apoptosis. 10 Family studies have shown that inherited factors may also have a role in the development of HL; individuals related to HL patients have more than a three-fold increased risk of developing HL, as shown by population [11] [12] [13] [14] [15] and twin studies. 16 Factors that are involved in EBV recognition and NF-kB activation are the Toll-like receptors (TLRs). Specifically, TLR9 recognizes viral CpG islands and, once activated, it signals through myeloid differentiation primary response protein 88 (MYD88) and leads to NF-kB activation. [17] [18] [19] Considering the importance of TLRs in NF-kB activation, one could hypothesize that these receptors may have a role in the abundant inflammatory background present in HL. To test this hypothesis, we chose to examine whether genetic variations in TLR9 and MYD88 are associated with the development of HL. Previous studies in HL 20 showed an odds ratio (OR) of 0.82 for TLR9-1237C that was of borderline significance, whereas weak associations were also detected for follicular lymphoma and chronic lymphocytic leukemia.
TLR9 is located on chromosome 3p21.3; 21 it consists of two exons and two single-nucleotide polymorphisms (SNPs) define the four most common haplotypes in Caucasians. 22 These include the À1237T4C (dbSNP rs5743836) and the synonymous 2848A4G (P545P) (dbSNP rs352140) SNP located in exon 2. TLR9 is in close proximity to the MYD88 gene, which is located on chromosome 3p22 and consists of five exons. 23 The À938C4A SNP (dbSNP rs4988453) and the 1944C4G (dbSNP rs4988457) SNP define the two most common haplotypes in Caucasians. 24 In this analysis, we undertook a gene-candidate association study to investigate whether the abovementioned polymorphisms contribute to the risk of HL.
MATERIALS AND METHODS Subjects
A total of 90 formalin-fixed paraffin-embedded tissue sections collected from HL patients were analyzed from the Pathology Laboratories of Hygeia Hospital (Athens, Greece), the Evaggelismos Hospital (Athens, Greece) and from the University Hospital of Larissa (Larissa, Greece). All patients were of Caucasian origin and met the World Health Organization criteria for classic HL. Peripheral blood samples were obtained from 92 healthy subjects from the University Hospital of Larissa (Larissa, Greece), after receiving informed consent. The control subjects were healthy individuals of Caucasian origin, with no known history of HL or any other disorder.
SNP genotyping
Case and control subjects were genotyped for the TLR9 (GenBank Accession No. NM_017442) and MYD88 (GenBank Accession No. NM_002468) SNPs of interest. After consecutive attempts, genotyping was successful for 86 HL cases and for 84 control subjects for the TLR9 À1237T4C SNP, for 90 cases and 90 controls for the TLR9 2848A4G SNP, for 90 cases and 87 controls for the MYD88 À938C4A SNP and for 86 cases and 89 controls for the MYD88 1944C4G SNP. PCR was used to amplify DNA fragments encompassing SNPs of interest in a typical reaction containing the 1Â PCR buffer, B30 ng genomic DNA, 1-1.5 mM MgCl 2 , 0.2 mM dNTPs, 0.2 mM of each primer and 1.25 Units Go Taq Flexi Polymerase (Promega, Southampton, UK). Samples were denatured for 5 min at 96 1C and subjected to 35 cycles of denaturation at 96 1C for 1 min, annealing at 56-64 1C (depending on the primers used) for 1 min and extension at 72 1C for 1 min, followed by an extension step at 72 1C for 5 min.
The TLR9 À1237T4C genotypes were determined by amplification of a 456 bp fragment of the 5¢-flanking region of TLR9 using primers 5¢-AAG AAG CTG ACA TTC CAG CAG GG-3¢ (forward) and 5¢-CTA GGT CCC TCC TCT GCT CAG AC-3¢ (reverse) at 64 1C annealing, followed by BstNI digestion of the PCR product. Digestion resulted in fragments of 31, 38, 48, 89, 112 and 186 bp in the presence of the T allele, and in fragments of 31, 38, 48, 89, 112 and 138 bp in the presence of the C allele. The TLR9 2848A4G genotypes were identified by amplification of a 371 bp fragment of exon 2 using primers 5¢-TGG ATC TGC CAC GGA ACA ACC-3¢ (forward) and 5¢-CAG CGA CGT ACT GCA GAG CTG-3¢ (reverse) at 62 1C annealing, followed by BstUI digestion. Digestion of the PCR product resulted in fragments of 226 and 145 bp in the presence of the G allele, and 371 bp in the presence of the A allele. The MYD88 À938C4A genotypes were determined by PCR amplification of a 503 bp fragment of the 5¢-flanking region of MYD88 using primers 5¢-GCA GCC AGG ACC GCT TACT GC T-3¢ (forward) and 5¢-GCA CGT GGC CTT GCC CTT GCC CTT TAG G-3¢ (reverse) at 62 1C annealing, followed by BsrI digestion of the PCR product. The expected fragment sizes after digestion were 23, 97, 165 and 218 bp in the presence of the C allele, and 97, 165 and 241 bp in the presence of the A allele. The MYD88 1944C4G genotypes were identified by amplification of a 448 bp fragment of intron 3 using primers 5¢-GCC CCA GCG ACA TCC AGT TTG TG-3¢ (forward) and 5¢-TCT TGC CAG AGC AGG GTT GAG CTT-3¢ (reverse) at 56 1C annealing, followed by Cac8I digestion. Digestion of the PCR products resulted in fragments of 92, 135 and 221 bp in the presence of the G allele, and in fragments of 135 and 313 bp in the presence of the C allele. At least 10% of the samples were randomly selected as an internal control for repeated genotyping.
Data analysis
The genotypes were tested for Hardy-Weinberg (HW) equilibrium and the loci were tested for linkage disequilibrium using exact tests according to Weir. 25, 26 The haplotype frequencies were estimated and compared using PHASE v2.1 (Seattle, WA, USA) (http://www.stat.washington.edu/stephens/). The disequilibrium and correlation coefficients were estimated according to Weir. 26 The genotype distribution, allele contrast and the dominant model (risk allele carriers) of the HL patients was compared with the control group using a loglinear model. 27 The comparisons were expressed in terms of OR unadjusted and adjusted for age and sex. A P-value of o0.05 was considered statistically significant.
RESULTS

Demographic characteristics of the study population
A total of 91 cases and 92 controls were analyzed in this study. The mean age (±s.d.) was 42.9±18.5 and 35.5±10.1 years for cases and controls, respectively; there were 44 (50.6%) males and 43 (49.4%) females in the case group, whereas the control group comprised 27 (29.3%) males and 65 (70.7) females. HL samples were of the following histological subtypes: nodular sclerosis (73 cases), mixed cellulary (15 cases) and lymphocyte rich (3 cases). The control subjects were younger and comprised a higher percentage of females than did the cases.
Genotype distributions and study quality
The distributions of the TLR9 À1237T4C, TLR9 2848A4G, MYD88 À938C4A and MYD88 1944C4G genotypes in both cases and controls are shown in Table 1 . Significant differences were detected in the distribution of genotypes of the two TLR polymorphisms between cases and controls (P¼0.01 for TLR9 À1237T4C and P¼0.03 for TLR9 2848A4G). In contrast, there were no differences for the MYD88 polymorphisms (P¼0.
The controls were in HW equilibrium for all investigated polymorphisms, indicating the lack of stratification and/or genotyping error 28 (P¼0.11 for TLR9 À1237T4C, P¼0.37 for TLR9 2848A4G, P¼0.99 for MYD88 À938C4A and P¼0.60 for MYD88 1944C4G).
Polymorphisms in TLR9 and association with HL Table 2 shows the association results for the TLR9 polymorphisms. The allele contrast showed that for the À1237C allele there was a twofold risk for HL relative to the À1237T allele (OR¼1.99 (1.18-3.36)). Furthermore, À1237C-carrier individuals were associated with a higher risk of HL unadjusted and adjusted for age and sex (OR¼2.53 (1.36-4.71) and OR¼2.02 (1.04-3.89), respectively).
With regard to the TLR9 2848A4G polymorphism, the allele contrast produced a marginal association (OR¼1.54 (1.00-2.39)). Role of TLR9 and MYD88 in HL V Mollaki et al 2848A carriers had an increased risk for HL, as the unadjusted OR was significant (OR¼6.20 (1.3-28.8)); however, the adjusted OR was marginally significant (OR¼4.66 (1.00-22.9)). TLR9 and MYD88 haplotype frequency in HL patients and control subjects Table 3 shows the P-values, and the respective D¢ and r 2 , for testing linkage disequilibrium between pairs of SNPs for HL patients and controls. In the patient population, TLR9 À1237T4C was in linkage disequilibrium with TLR9 2848A4G (Po0.01), MYD88 À938C4A (P¼0.04) and MYD88 1944C4G (P¼0.05). TLR9 2848A4G was also found in linkage disequilibrium with MYD88 À938C4A (Po0.01) in HL patients. In controls, the two MYD88 polymorphisms were in linkage disequilibrium (Po0.01) ( Table 3 ). The distribution of the estimated haplotype frequency of the two TLR9 polymorphisms and the two MYD88 polymorphisms for the HL and controls is presented in Table 4 . Regarding the TLR9 haplotypes, there was an overall significant difference between the HL and controls (P¼0.03). This difference was due to the 1237C-2848A haplotype (or the 1237T-2848G haplotype) (Po0.01). For the MYD88 haplotypes, the overall difference was not significant (P¼0.20). However, the estimated frequency of the haplotype 938C-1944G was different in HL and controls; this difference might be due to the linkage disequilibrium with the TLR9 polymorphisms or because of the interaction between the two polymorphisms, given that the individual MYD88 polymorphisms were not significant.
Polymorphisms in the MYD88 gene and association with HL
When the estimated haplotypes of the four investigated polymorphisms were considered (Table 5 ), a significant difference between HL and controls was observed for the 1237T-2848G-938C-1944C and the 1237C-2848A-938C-1944C haplotypes (Po0.01), further indicating the association of 1237T and 2848G alleles (or allele carriers) with HL susceptibility.
DISCUSSION
This study investigated whether certain TLR9 and MYD88 gene polymorphisms were associated with the development of HL. Our results showed that the TLR9 À1237C allele confers a two-fold increased risk of HL and that the TLR9 2848A allele increased HL risk by B4.5-fold in the Caucasian population examined. None of the MYD88 SNPs analyzed (MYD88 À938C4A and MYD88 1944C4G) were found to alter the susceptibility to HL. The genotype distributions of the SNPs examined were all in HW in the control group, indicating no population stratification. Haplotype analysis also Role of TLR9 and MYD88 in HL V Mollaki et al
showed that the distribution of the TLR9 1237C-2848A haplotypes were different between cases and controls.
Others have also examined the role of TLRs and particularly that of TLR9 gene polymorphisms in susceptibility to human diseases associated with altered immune responses and inflammation. Among the other TLR polymorphisms, Nieters et al. 20 investigated the contribution of the TLR9 À1486T4C and À1237T4C SNPs to the development of lymphomas, including 115 cases of HL. A 20% decreased risk of all lymphomas was associated with the TLR9 À1237C allele, but this was of borderline significance. In contrast to our study, no contribution of the À1237T4C SNP to HL was found.
Although significant associations were detected in our study, the size was relatively small. However, candidate-gene association studies have the tendency to lack the power to detect a statistically significant association. For example, to achieve a power of 480% to identify a modest genetic effect (OR¼1.2) of a polymorphism present in 10% of individuals, a sample size of X10 000 subjects would be required. 28 Therefore, the sample sizes required to predict association have to be far beyond what is currently available and no single institution or entity alone will be able to provide a reasonable number of patients. However, a future meta-analysis of multiple studies clearly has a role in offering an analysis with the potential for higher power. 28, 29 Future collaborative studies may allow the pooling of data, providing more power to detect significant associations. Furthermore, consortia performing gene-candidate or genome-wide association studies will be able to replicate the validity of the present findings.
This study was based on the hypothesis that genetic variations in TLR9 and MYD88, both of which have crucial roles in immunity and inflammation, could alter the downstream immunological responses after NF-kB activation. Given that increased NF-kB activation is a characteristic of HL cell lines and is required for the proliferation and survival of RS cells, 3 TLR expression variability could participate in the pathogenesis of HL. This hypothesis was further supported by the fact that EBV has been repeatedly associated with the development of HL and that, on EBV infection, LMP1 constitutively transmits signals that activate NF-kB. 10 So far, the functional role of the TLR9 À1237T4C polymorphism seems controversial. Deletions spanning the À3.2 to À0.7 kb promoter region did not alter the TLR9 promoter activity, 30 although the region was shown to be important for the Human Papillomavirus 16-mediated inhibition of TLR9 expression. 31 In silico analysis of the TLR9 promoter showed that the À1237T4C change introduces a putative c-Rel/NF-kB transcription factor binding site; 32 in vitro gene reporter assays showed that the TLR9 À1237T4C SNP alters the TLR9 promoter activity, with the À1237T allele having a higher promoter activity (P¼0.018), suggesting the existence of regulatory elements across the polymorphic site 33 and implying that the À1237C allele is associated with lower TLR9 expression levels.
In conclusion, this study showed that a genetic variation in TLR9 may alter the susceptibility to HL. Although the functional significance, if any, of the TLR9 À1237T4C and the TLR9 2848A4G SNPs remains to be elucidated, our results suggest that TLR9 polymorphisms and TLR9 and MYD88 haplotypes may be involved in the pathogenesis of HL. Role of TLR9 and MYD88 in HL V Mollaki et al
